State Street’s ABVC BioPharma ABVC Stock Holding History

State Street’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$115K	Hold	72,800	–	–	﹤0.01%	3949
2026 Q1	$70.6K	Hold	72,800	–	–	﹤0.01%	4084
2025 Q4	$155K	Hold	72,800	–	–	﹤0.01%	3957
2025 Q3	$221K	Buy	72,800 +59,900	+464%	+$184K	﹤0.01%	3883
2025 Q2	$28.7K	Hold	12,900	–	–	﹤0.01%	4167
2025 Q1	$13.7K	Hold	12,900	–	–	﹤0.01%	4240
2024 Q4	$7.61K	Hold	12,900	–	–	﹤0.01%	4284
2024 Q3	$8.82K	Hold	12,900	–	–	﹤0.01%	4269
2024 Q2	$9.98K	Buy	+12,900	New	+$13.2K	﹤0.01%	4322

Other funds holding ABVC

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street's ABVC Position: Q2 2026 in Review

State Street held its ABVC BioPharma (ABVC) position steady in Q2 2026 at 72,800 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #3949.

State Street first reported a position in ABVC in Q2 2024 and has held it in 9 quarters since. The position peaked at $221K in Q3 2025. 15 funds tracked by Wall St. Rank hold ABVC as of Q2 2026.

State Street held 72,800 shares of ABVC BioPharma worth $115K as of Q2 2026.
State Street left its ABVC BioPharma share count unchanged in Q2 2026.
ABVC BioPharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3949 holding.
State Street first reported a position in ABVC BioPharma in Q2 2024 and has held it in 9 quarters since.
State Street's ABVC BioPharma position peaked at $221K in Q3 2025.
15 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.